Okana Ventures Inc. (OTCBB:OKNV) acquired Factive product from Merus Labs International Inc. (TSX:MSL) for $3.4 million in cash and stock on August 26, 2013. The consideration comprises of a cash payment of $2.2 million paid on closing, a non-contingent deferred note payment of $0.8 million to be paid in quarterly installments over the next 15 months, and 3 million shares of OKNV common stock. Factive reported revenues of CAD $1.09 million ($1.11 million) and net income of CAD 0.22 million ($0.25 million) for the period ending September 30, 2012. Under the transaction, Okana acquired the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets. Merus divested the license to the FACTIVE(r) trademark and patent, inventory on hand, various contingent liabilities, and certain related intellectual property and other information and materials required to market the brand in the North American market. The conversions were done through www.oanda.com as on September 30, 2012.

Okana Ventures Inc. (OTCBB:OKNV) completed the acquisition of Factive product from Merus Labs International Inc. (TSX:MSL) on August 26, 2013.